Our In Vitro Services Include a Large Cohort of Validated and Well-Characterized Cell Lines
CrownBio offers a variety of in vitro platforms for your oncology drug discovery program.
At CrownBio we are committed to saving you precious time and resources by providing efficient screening platforms and validated cell lines, giving you confidence in your data.
Our large team of international scientists have extensive experience working with Pharmaceutical and Biotechnology companies to support the in vitro pharmacology characterization of lead compounds.
Select from our Collections of Generic or Focused Cancer Cell Lines
OmniPanel™, a genomically diverse collection of more than 500 cancer cell lines for drug response screening
XenoSelect™, a diverse oncogenic in vitro screening panel of over 150 well-validated cell lines, with associated Cell Line Derived Xenograft models ready for in vivo efficacy studies
RNAseq Panel, more than 170 in-house genomically characterized cell lines to correlate mutation status, copy number variation, and expression levels with drug response
A Comprehensive Range of Functional Assays
CrownBio’s extensive tool sets to determine the biological functions of each target, and to help you take go/no go decisions, include a variety of functional assays such as:
- High throughput cytotoxicity screening
- In vitro drug combination studies
- 3D clonogenic assays
- 3D Tumor Growth Assays using PrimePanel cell lines
- Target validation studies
- Adhesion, migration, and invasion assays
- Angiogenesis assays
- Apoptosis studies
- ADCC and CDC analyses
- Cell cycle analysis
- Pharmacodynamics/Pharmacokinetics analysis
Immuno-Oncology In Vitro Screening
Cancer immunotherapy is coming of age as a treatment paradigm, however, development of new immunotherapeutics still faces many challenges. Testing new immuno-oncology compounds in vitro, before moving to the in vivo setting, has proved challenging for many new drugs such as biological agents.
CrownBio offers a wide range of assays and platforms for in vitro testing of immuno-oncology agents, including core immunophenotyping, functional assays, and technologies for the regulation of the tumor microenvironment, allowing you to move with confidence to the next phase of drug development.
Frequently Asked Questions
How many cell lines are currently in your bank?
Our bank consists of more than 500 cell lines of human origin and more than 300 murine cell lines. The vast majority of our collection consists of cancer cell lines but we also have a number of models originated from non-tumor tissue such as fibroblasts or myoblasts and several engineered cell lines that express targets of interest or luciferase reporters to track target gene expression or tumor growth.
How many cancer types does your collection cover?
Our collection covers more that 20 different cancer types and subtypes.
How can I access your cell line list?
The most efficient option is using our cell line and cell line derived xenograft model database XenoBase®. Access to our database is free for registered users and provides a wealth of information and characterization data on our models, including genomic and pharmacological data. Alternatively, clients can contact the Business Development Representative in their area or our contact center via our webiste at https://www.crownbio.com/contact-us.
Have you developed any matched in vivo xenograft models from your cell line collection?
Yes, around 200 cell line derived xenograft models have been successfully established and extensively characterized for their growth profile and pharmacological response to multiple agents, including current standard of care for the specific cancer type.
What assays can you run?
The list of assays that we can run is fairly extensive and includes proliferation, invasion and migration, apoptosis/cell death detection, cell cycle analysis, colony formation assays, etc. Additionally, we work with our clients and customize assays and read outs to fit their drug development needs. A comprehensive list of available assays can be found via our Global Capabilities document.
Are any of your cell lines available in a 3D format?
Yes, more than 140 immortalized cell lines and over 200 cell lines derived from our PDX models have been validated for growth in a 3D format and have been successfully used for drug screening services. Additionally, thanks to our partnership with Hubrecht Organoid Technology we are able to offer unique and clinically-relevant tumor organoids for oncology drug development.
Can you run cell line screening services?
Yes, we offer a routine screening service called OmniScreen. Clients choose from 50 or more cell lines from our collection to investigate their compound potency and efficacy as single agents or in combination.
What type of characterization data is available on your cell lines?
Our cell lines are all mycoplasma tested and STR verified and extensively characterized for their genomic (including mutations, amplifications, and fusion) and gene expression profiles (carried out by both RNAseq and microarrays) as well as for pharmacological response. Lately we have expanded these characterization profiles to include analysis of the proteome and HLA profiling.